Avidity Biosciences (RNA) PT Raised to $62 at Barclays
Tweet
Share
E-mailGet Alerts RNA Hot Sheet
Price: $12.84 +4.14%
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays analyst Gena Wang raised the price target on Avidity Biosciences (NASDAQ: RNA) to $62.00 (from $59.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Atrium Therapeutics Reports Second Quarter 2026 Financial Results
- Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
- Tata Motors Passenger Vehicles (TMPV:IN) PT Raised to INR375 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
